CervoMed Names Matthew Winton as Chief Commercial and Business Officer

Written by Emily J. Thompson, Senior Investment Analyst

INZY%

CRVO+2.82%

Updated: Oct 07 2025

0mins

New Appointment: CervoMed (CRVO) has appointed Matthew Winton, Ph.D., as Chief Commercial and Business Officer.
Previous Experience: Prior to joining CervoMed, Dr. Winton was the COO at Inozyme Pharma (INZY).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

CervoMed Names Matthew Winton as Chief Commercial and Business Officer

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Trump Denies Nominating JPMorgan CEO Dimon for Fed Chair

Trump Denies Considering JPMorgan's Dimon for Fed Chair Position

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch